NSW2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (WITHDRAWN)2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (WITHDRAWN)2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (WITHDRAWN)

VIC3168 - Clayton - Monash Medical Centre (COMPLETED)

WA6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (COMPLETED)

NANA (WITHDRAWN)

NCT05886920

A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations (D3S-002-100)

2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (COMPLETED)

SA5042 - Bedford Park - Flinders Medical Centre (COMPLETED)

WA6009 - Nedlands - Linear Clinical Research (COMPLETED)

NCT05696626

An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEIII)

NCT05669989

International, Multi-center, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Are Still Benefitting From Isatuximab-based Therapy Following Completion of a Phase 1, 2, or 3 Parental Study (LTS17704)

NCT05523947

A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32367 in Patients With HER2-Positive Locally Advanced or Metastatic Solid Tumors (YH32367-101)

VIC3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (WITHDRAWN)

SA5042 - Bedford Park - Southern Oncology Clinical Research Unit (TERMINATED)

WA6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (WITHDRAWN)

NCT05269316

A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation and Dose-expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of the ATR Inhibitor IMP9064 Monotherapy and in Combination With PARP Inhibitor Senaparib in Patients With Advanced Solid Tumors (IMP9064-101)

NSW2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (COMPLETED)

WA6009 - Nedlands - Linear Clinical Research (COMPLETED)

NCT04895709

A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors (CA052-002)

ACTRN12621001537842

Safety and Efficacy of NOX66 in combination with Nivolumab for patients with solid tumours – a pilot study (IONIC-1). (CA209-66P,)

ACTRN12621000586819

A phase II study of platinum and etoposide chemotherapy, durvalumab with thoracic radiotherapy in the first line treatment of patients with extensive-stage small-cell lung cancer (TROG-20.01-CHEST-RT)

NCT04205227

A Phase 1/2A Trial of ENB 003 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors (MK3475-951)

PD-1/PD-L1	28%
PD-1	25%
ERBB2	13%
EGFR	11%
oestrogen axis	9%
VEGF	6%
CDK4	6%
KRAS	6%
ER	6%
Bcl2	6%
B7H3	6%
Trop2	6%
FR-alpha	5%
CDK4 selective	5%
PI3Kalpha	5%
MET	5%
ERBB3	5%
PD-L1	5%
VEGFA	5%
cereblon	5%
CDK6	3%
BTK	3%
CDK2	3%
SMO	3%
TIGIT	3%
BCMA	3%
B7H4	3%
proteasome	3%
CALR	2%
KAT6A	2%
CD20	2%
CLDN6	2%
CTLA4	2%
DNA methyltransferase	2%
GPR65	2%
FGFR2	2%
FGFR2b	2%
CEACAM5	2%
MAT2A	2%
PRMT5	2%
CS1	2%
AR	2%
CYP17A1	2%
androgen axis	2%
MUC18	2%
ERK	2%
CD38	2%
4-1BB	2%
ATR	2%
PARP	2%
CCR8	2%
ETBR	2%

ARTICANZ - Beta (ver 0.91)

Search results

Filters